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In Brief
Murakami et al. show that FUS transitions
between monomer, liquid droplet, and
hydrogel states during uptake and
release of RNP granule cargo. FUS
mutations accelerate transition into
fibrillar hydrogels that trap RNP cargo,
impair RNP granule function, and cause
neurodegeneration.
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The mechanisms by which mutations in FUS and
other RNA binding proteins cause ALS and FTD
remain controversial. We propose a model in which
low-complexity (LC) domains of FUS drive its physio-
logically reversible assembly into membrane-free,
liquid droplet and hydrogel-like structures. ALS/
FTD mutations in LC or non-LC domains induce
further phase transition into poorly soluble fibrillar hy-
drogels distinct from conventional amyloids. These
assemblies arenecessary andsufficient for neurotox-
icity in a C. elegans model of FUS-dependent neu-
rodegeneration. They trap other ribonucleoprotein
(RNP) granule components and disrupt RNP granule
function.Oneconsequence is impairment of newpro-
tein synthesis by cytoplasmic RNP granules in axon
terminals, where RNP granules regulate local RNA
metabolism and translation. Nuclear FUS granules
may be similarly affected. Inhibiting formation of
these fibrillar hydrogel assemblies mitigates neuro-
toxicity and suggests a potential therapeutic strategy
that may also be applicable to ALS/FTD associated
with mutations in other RNA binding proteins.678 Neuron 88, 678–690, November 18, 2015 ª2015 The AuthorsINTRODUCTION
Mutations in a growing list of RNA binding proteins (RBPs)
including TDP-43, FUS, ataxin2, hnRNPA1, and B2, are asso-
ciated with sporadic and inherited forms of amyotrophic lateral
sclerosis and frontotemporal dementia (hereafter ‘‘ALS/FTD’’)
(van der Zee and Van Broeckhoven, 2014). A neuropatholog-
ical hallmark of these disorders is the deposition of poorly sol-
uble assemblies of the mutant RBP in the nucleus and cyto-
plasm of neurons in the brain and spinal cord of ALS/FTD
patients.
The pathogenic significance of these intraneuronal assemblies
has been the subject of much speculation. Hypotheses have
included that they might (i) be irrelevant secondary phenomena,
(ii) form conventional neurotoxic amyloids, or (iii) bind and trap
crucial RNA sequences (Couthouis et al., 2011; Gendron et al.,
2010; Neumann et al., 2007; Rademakers et al., 2012; Ticozzi
et al., 2010). Although there are data to support the notion that
these aggregates may be amyloid like (Fang et al., 2014; Robin-
son et al., 2013), other evidence suggests that they are distinct
from classical amyloids (Cairns et al., 2007; Dormann et al.,
2009; Murakami et al., 2012). Specifically, we and others have
shown that in contrast to classical amyloids, pathological RBP
deposits are (1) soluble in urea, (2) have low b sheet content,
(3) have a mixed granular/fibrillar appearance under EM, (4) do
not bind amyloidophyllic dyes (e.g., Thioflavin T), and (5) when
fluorescently labeled, do not display the marked reductions in
in vivo fluorescent lifetimes that are typical of conventional amy-
loids (Kaminski Schierle et al., 2011) (Figures S1–S3).
Recently, attention has refocused on the possibility that
mutant ALS/FTD-associated RBPs might be incorporated into
and alter the function of ribonucleoprotein (RNP) granules (Li
et al., 2013; Mitchell and Parker, 2014; Ramaswami et al.,
2013; Wolozin, 2012). However, these hypotheses have not
been directly proven.
To investigate this possibility, we utilized FUS as a tractable
example of the RBP-proteinopathies. We describe here the
results of an extensive array of biophysical, biochemical,
cellular, and animal model experiments conducted over the
past 4 years. In partial agreement with earlier reports (Han
et al., 2012; Kato et al., 2012), we show that in a process driven
by the LC domain at the N terminus of FUS, FUS undergoes
phase transitions, reversibly shifting between dispersed, liquid
droplets, and hydrogel-like phases. Crucially, we demonstrate
that pathogenic FUS mutants severely limit this ability to reiter-
atively shift between these phases. In fact, FUS mutants in-
crease the propensity of FUS to condense into poorly soluble,
stable, fibrillar hydrogel-like assemblies. We show that these
stable ‘‘irreversible’’ FUS assemblies: selectively entrap other
ribonucleoproteins, impair local RNP granule function, and
attenuate new protein synthesis in the axon terminals of
cultured neurons. We do not exclude the possibility that forma-
tion of fibrillar hydrogels may have similar disruptive effects on
nuclear RNP granules. Importantly, we show that modulation of
these protein phase transitions may be a tractable therapeutic
strategy.
RESULTS
To rigorously test the idea that mutations in FUS alter its assem-
bly into RNP granules, we first explored the biology of FUS in
a C. elegans model of FUS proteinopathy (Murakami et al.,
2012). In this model, equivalent levels of wild-type or mutant
human FUS protein are expressed under the neuron-specific
Prgef-1 promoter with a GFP tag, which does not alter the activ-
ity or location of FUS (Murakami et al., 2012). We focused on
animals (n R 3 lines per mutant) expressing wild-type FUS
(FUS(WT)) or one of five ALS/FTD mutants: FUS (R495X),
FUS(R522G), FUS(R524S), FUS(P525L), and FUS501(which
models several ALS/FTD-associated C-terminal truncating mu-
tations) (Figure 1A). These mutations span a wide range of pre-
dicted aggregation propensities as calculated using the Zyggre-
gator method (Tartaglia and Vendruscolo, 2008): FUS(R495X):
Zagg = 0.44; FUS(R522G): Zagg = 0.09; FUS(R524S): Zagg =
0.05; FUS(P525L): Zagg = 0.12; FUS501: Zagg = 0.52 (Figure S4).
The aggregation propensities of these mutants correlate with
their phenotypic severities in C. elegans and in humans, ranging
from mild (R522G) to severe (FUS (P525L), FUS (R495X), and
FUS501) (Murakami et al., 2012) (Figure S5).
This C. elegans model displays several features observed in
human FUS-related disorders (Murakami et al., 2012). Thus, in
animals expressing wild-type FUS, FUS is expressed physiolog-
ically in the nucleus, and causes no detectable neurotoxicity
(Figures S6 and S7). In contrast, animals expressing mutantFUS display age-dependent neurotoxicity manifested by im-
paired motor function and reduced lifespan (Figures S7 and
S8). These phenotypes are accompanied by nuclear and cyto-
plasmic deposits of FUS that are insoluble in high-salt and
RIPA buffers but are soluble in 8 M urea (Figure 1B). The
ex vivo abundance of these 8 M urea-soluble species correlates
with the in vivo abundance of visible cytoplasmic FUS assem-
blies in neurons (r2 = 0.96) (Figure S8). As is the case in human
brain expressing mutant FUS, these pathological FUS assem-
blies are biochemically and biophysically distinct from conven-
tional neurotoxic amyloids (Figures S1–S3).
Non-Amyloid 8 M Urea-Soluble FUS Assemblies Cause
Neurotoxicity
Two lines of evidence indicate that FUS assemblies drive neuro-
toxicity. First, in animals expressing equivalent quantities of total
FUS protein, the abundance of 8Murea-soluble FUS assemblies
correlates directly with neurotoxicity as measured by motor ac-
tivity (r2 = 0.69) and lifespan (r2 = 0.88) (Figure S7). Second, within
each line, neurotoxicity can be increased or decreased by
manipulating the abundance of the 8M urea-soluble assemblies.
In lines expressing ALS/FTD-associated mutant FUS, increasing
the abundance of these 8 M urea-soluble assemblies (e.g., by
heat-stress-induced depletion ofmolecular chaperones) exacer-
bated motor deficits and accelerated mortality (Figure S9; p <
0.01; n = 16 animals/ strain). Conversely, reducing the abun-
dance of 8 M urea-soluble assemblies, either by treatment with
protein aggregation inhibitors such as scyllo-inositol, or by over-
expression of hsp-70, rescued both motor function andmortality
of mutant FUS strains but not in non-transgenic N2 or FUS(WT)
animals (Figure S10; scyllo-inositol: p < 0.01; n = 20 animals/
strain; hsp-70: p < 0.001, n = 20 animals/strain).
Neurotoxicity Is Driven by the FUS Low-Complexity
Domain
The N-terminal low-complexity (LC) domain of FUS (residues
2–214) has been reported to induce the assembly of wild-type
FUS into hydrogel-like assemblies (Han et al., 2012; Kato et al.,
2012). Consistent with this observation, calculation of the bio-
physical aggregation propensity of FUS revealed that the LC
domain is highly prone to aggregate. However this tendency is
offset by the lower aggregation propensity of the C-terminal do-
mains (Figure S4). Taking these observations together, we hy-
pothesized that (1) ALS/FTD mutations in the FUS LC domain
(e.g., S96del and G156E) might directly increase the propensity
of the LC domain to induce FUS assembly into higher order
structures; while (2) ALS/FTD mutants in the C terminus would
indirectly have the same effect by reducing the anti-aggregation
effect of the C terminus (Figure S4).
In agreementwith thesepredictions, animals expressingmutant
FUS constructs lacking the LC domain had significantly less 8 M
urea-soluble assemblies and less neurotoxicity (Figure 1C; n =
20 animals/strain; p < 0.01 for 8 M urea FUS and lifespan; p <
0.001 for thrashing score; Figure S11). Conversely, expression of
FUS(LC) alone induced robust 8 M urea-soluble assemblies
accompaniedby increasedmotordeficitsandmortality (Figure1D,
p < 0.01, Figure S12; p < 0.001; n = 20 animals/line). As predicted,
the severity of these FUS(LC)-induced phenotypes was furtherNeuron 88, 678–690, November 18, 2015 ª2015 The Authors 679
Figure 1. FUS Constructs, Cellular Locali-
zation, and Neurotoxicity of Mutant FUS
(A) FUS constructs and mutations. Full-length
FUS constructs include wild-type FUS(WT) and
ALS/FTD mutations (R522G, R524S, P525L, and
R495X), or FUS (FUS501), which mimics several
ALS/FTD truncation mutants. LC motif at residues
2–214 was deleted in FUS(WT)DLC, FUS(P525L)
DLC, and FUS501DLC. FUS(LC)-only constructs
include wild-type FUS(LC), pathogenic S96del
or G156E mutants, or clinically benign P21H
and N63S sequences. LC, low-complexity motif;
G-Rich, glycine-rich region; RRM, RNA recogni-
tion motif; RGG-rich, arginine-glycine-glycine-rich
region.
(B) FUS(WT) is located in neuronal nuclei; mutant
FUS accumulates as 8 M urea-soluble assemblies
in neuronal cytoplasm. Western blot of high-salt
buffer extracted whole-worm lysates (top), 8 M
urea extracted lysates (middle), and a-tubulin
(bottom).
(C) FUS LC domain is necessary and sufficient for
FUS assembly and neurotoxicity. Deletion of LC
domain from FUS(P525L) and FUS 501 reduces
formation of 8 M urea-soluble FUS (left panel),
improves motor function (middle panel), and life-
span in mutant FUS lines (right panel), but has no
impact on FUS(WT) animals. N.S., not significant.
**p < 0.01; ***p < 0.001.
(D) FUS LC domain is necessary and sufficient
for FUS assembly and neurotoxicity. Over-
expression of wild-type FUS(LC) alone is associ-
ated with increased 8 M urea-soluble assemblies
(left panel), impaired motor function (middle
panel), and lifespan (right panel). The ALS/FTD
FUS(LC)-mutations (S96del and G156E) further
augment neurotoxicity. *p < 0.05, **p < 0.01, and
***p < 0.001.
Error bars are SEM.enhanced in animals expressing FUS(LC) domain containing the
ALS/FTD associated mutants: S96del or G156E (Figure 1D; p <
0.05; n = 20 animals /line, 3 replications; Figure S12).
Manipulation of Other Components of FUS-Containing
RNP Granules Rescues Toxicity
Pathological FUS assemblies contain other components of RNP
granules including other RNA-binding proteins (Li et al., 2013;
Mitchell and Parker, 2014; Ramaswami et al., 2013; Wolozin,
2012). We wondered whether some of these other components
may stabilize FUSassemblies, as is the casewithmanyother het-
eromeric complexes. If so, then knockdown of a subset of these
RNP granule components might destabilize the pathological
complexes and ameliorate neurotoxicity. We selected seven
RNPs that (1) are components of RNP granules, (2) have human
andC. elegans homologs, and (3) have validated neuron-special-
ized RNAi clones available to knock down the C. elegans homo-
log. This list comprised CBP (cbp-1), EIF2AK (pek-1), EIF2AK3
(gcn-2), STAU-1 (stau-1), SMN (smn-1), hnRNP1 (hrp-1), and
TIA-1 (tiar-1) (upper case=human; lower case=C.elegansortho-680 Neuron 88, 678–690, November 18, 2015 ª2015 The Authorslog). RNAi of cbp-1 was uninterpretable because it caused non-
specific effects in non-transgenic animals. RNAi of tia-1, hrp-1,
gen-2, andpek-1did not alter thrashing scores, lifespan, or abun-
dance of 8 M soluble FUS levels in animals expressing FUS(WT),
mutant FUS, or FUS(LC) (white bars in Figures 2A–2C; p =N.S). In
contrast, RNAi knockdown of stau-1 or smn-1 partially rescued
neurotoxicity, reduced 8 M urea-soluble FUS assemblies, and
reduced visible cytoplasmic FUS deposits in all mutant FUS
strains tested (gray bars in Figures 2A–2C and S13; p < 0.05,
n = 20 animals/strain, three replications).
To determine whether the rescue effect was mediated at the
level of FUS granules, we co-expressed RFP-tagged STAU-1
or SMN in animals expressing various FUS cDNAs. STAU-1
andSMNstrongly colocalized (R72%±5.3%overlap) with cyto-
plasmic assemblies comprised of mutant full-length FUS or
aggregation-prone FUS(LC) domain. STAU-1 and SMN did not
colocalize with FUS(WT) (6.0% ± 3.1%; Figures 3D and S14;
n = 20 neurons; p < 0.001).
The colocalization of STAU-1 and SMN with mutant 8 M urea-
soluble FUS granules was semi-specific. Thus hnRNP1, which
Figure 2. Selected RNA Binding Proteins
Co-Localized with FUS in Mutant FUS As-
semblies and Their RNAi Knockdown Par-
tially Rescued Neurotoxicity
(A) A directed RNAi screen of selected LC-domain
containing RBPs revealed that RNAi knockdown
of SMN (smn-1) and STAU-1 (stau-1) (gray bars)
partially rescued motor function, whereas control
RNAi knockdown (blackbars)andRNAiknockdown
of TIA-1 (tiar-1), hnRNP (hrp-1), EIF2AK (pek-1), and
EIF2AK3 (gcn-2) (white bars) had no effect (N.S, not
significant; *p < 0.05 and **p < 0.01).
(B) RNAi knockdown of SMN and STAU-1 (gray
bars) rescued lifespan, whereas RNAi of the other
RNPs (white bars) and control RNAi (black bars)
had no effect. N.S., not significant. *p < 0.05 and
**p < 0.01.
(C) RNAi knockdown of SMN and STAU-1 (gray
bars) reduced 8 M urea-soluble FUS assemblies
whereas control RNAi (black bars) and RNAi of the
other RNPs (white bars) had no effect. N.S: not
significant. *p < 0.05; **p < 0.01.
Error bars are SEM.has no effect on FUS toxicity (Figures 2A–2C), poorly colocalized
with mutant FUS assemblies (Figure 3; hnRNP1 colocalization:
FUS(WT) and FUS501 % 6.0% ± 3.1%; p = N.S.). We have re-
ported similar lack of colocalization for PAB-1 (Murakami et al.,
2012). Intriguingly, TIAR-1, which is a known component of
stress granules, did colocalize with pathological cytoplasmic
FUS assemblies, and as described below, its presence inmutant
FUS granules may have functional significance (TIAR-1 colocal-
ization: FUS(WT) = 2.0% ± 2.0%; FUS501 = 84.0% ± 5.0%; p <
0.001) (Figure 3). Taken together, these results suggest that
pathological FUS assemblies selectively trap other RNPs. This
conclusion led us to ask two further questions. First, could phys-
iological FUS assemblies form reversible structures that tran-Neuron 88, 678–690, Nsiently sequester RNP cargo upon gel-
formation, but then release it upon
melting? Second, do irreversible FUS as-
semblies permanently trap their RNP
cargo?
FUS LC Domain Induces Reversible
Liquid Droplet and Hydrogel
Formation
To address these questions, we began
by exploring the impact of FUS mutations
on RNP granule formation in SHSY5Y
mammalian neuronal cells transiently
transfected with YFP-tagged wild-type
FUS, P525L, or FUS501 constructs. As
was the case in vivo in our C. elegans
model, in cells expressing YFP-tagged
wild-type FUS, FUS was predominantly
localized as spherical intranuclear drop-
lets (Figure 4A, left panel). In cells express-
ing YFP-tagged mutant FUS, FUS was
present as similar structures in the cyto-plasm and nucleus. Live cell imaging revealed that the nuclear
droplets were static, but the cytoplasmic droplets were motile
and on occasion fused with each other in a process previously
likened to liquid droplets (Brangwynne et al., 2009) (Figure 4A,
left panel).
To investigate the biophysics of FUS assembly into these liquid
droplet assemblies, and to test the hypothesis that mutations in
FUS might alter the dynamics of this process, we expressed and
purified recombinant wild-type full-length FUS and full-length
FUS containing one of five different mutations (FUS(R522G),
FUS(R524S), FUS(P525L), FUS501, and FUS(G495X)). At 23C in
near-physiological protein and salt concentrations (1–5 mM pro-
tein; 150 mM NaCl), all of the FUS proteins were fully dispersedovember 18, 2015 ª2015 The Authors 681
Figure 3. STAU-1, SMN, and TIAR-1 but Not
hnRNP1 Colocalize with Mutant FUS in
Cytoplasmic RNP Granules
STAU-1, SMN, and TIAR-1 (red) colocalized
with pathological intraneuronal cytoplasmic and
axonal assemblies of mutant full-length FUS501,
wild-type FUC-LC domain and mutant FUS(LC)
domain (green) but did not colocalize with nuclear
FUS(WT) (green). ***p < 0.001. Scale bars, 2.0 mm.
Additional data are shown in Figures S3B–S3D.
STAU-1 colocalization: FUS(WT) = 6.0% ± 3.1%;
FUS501 = 72.0 ± 5.3%; FUS(LC) = 80.0 ± 5.2%;
FUS(LC)-S96del = 95.0 ± 1.7%; FUS(LC)-G156E =
95.0 ± 2.2; n = 20 neurons; p < 0.001; SMN
colocalization: (FUS(WT) = 15.0 ± 3.1%; FUS
501 = 85.0 ± 3.4%; FUS(LC) = 84.0 ± 3.1%;
FUS(LC)-S96del = 89.0 ± 2.3%; FUS(LC)-G156E =
88.0 ± 2.5%; n = 20 neurons; p < 0.001). Scale
bars, 2.0 mm. Error bars are SEM.in solution.Whencooled to 4C to reduce thermalmotionand thus
stabilize weak interactions, they all assembled into visible liquid
droplets that frequently fused with each other over timescales of
20–40 s (Figure 4A, right panel). When droplets composed of
FUS(WT) were maintained at 23C, they almost completely dis-
solved within 50 min (Figure 4B). In contrast, when liquid droplets
composed of mutant FUS were treated in the same way,
more than 50% of mutant FUS assemblies persisted at 50 min
(Figure 4B, p < 0.01 n = 3 replications). Crucially, several of the
full-length FUS mutants (especially FUS (R524S)) and all of the
LC-domain constructs tended to produce dark, angled, or spicu-
latedstructures,whichwe interpretedtobesolid (Figure4B).These
analyses suggest that pathogenic FUS mutations favor phase
transitions of FUS from a monomeric dispersed state into a liquid
droplet and then into amore stable solid form. These observations
were robust but were difficult to quantify in detail because liquid
droplet formation is exquisitely sensitive to changes in ionic
strength and temperature of the buffer.
ALS/FTD-Associated Mutations in the FUS LC Domain
Alter Hydrogel Properties
To quantitatively assess the biophysical features that govern
phase transition of FUS from soluble monomer to reversible682 Neuron 88, 678–690, November 18, 2015 ª2015 The Authorsliquid droplet and then to more stable
assemblies, and to assess the conse-
quences of these phase transitions,
we adapted a previously published
method (Han et al., 2012; Kato et al.,
2012) that provides a simple and trac-
table platform to produce a working
model of reversible (physiological)
and irreversible (pathological) assembly
of FUS into higher-order structures.
Briefly, when 0.25–1 mM solutions of
wild-type FUS(LC) in 200–500 mM
NaCl are cooled to 4C, they condensed
into gels. Upon rewarming to 23C, the
gels re-dissolve into a clear solution(Figure 5A). This liquid/gel/liquid cycle can be assayed by
placing the protein solution into a siliconized microtube and
then varying the temperature between 4C and 23C. Liquid
assemblies readily fall under gravity when the tube is in-
verted. Gelled assemblies remain at the bottom of the tube
(Figure 5A).
Using this assay, wild-type FUS(LC) (Figure 5B, black bar, left
panel) and FUS(LC) domains containing either of the non-path-
ogenic variants (P2IH or N63S) all cycled four to five times
before becoming irreversibly gelled (Figure 5B, white bars, left
panel). In contrast, the ALS/FTD-associated mutant FUS(LC)
proteins (S96del or G156E) became irreversibly gelled within
two cycles (Figure 5B, gray bars, left panel, p < 0.01, n = 4
replications).
Recombinant FUS assemblies generated in this way displayed
biochemical and biophysical characteristics identical to those of
FUS assemblies observed in tissues from humans and from our
C. elegans models. Thus, the ungelled, liquid FUS(LC) domain
was fully soluble in RIPA buffer, like wild-type FUS in normal hu-
man andC. elegans tissues. In contrast, the irreversibly gelled re-
combinant FUS(LC) domains, regardless of whether generated
bymultiple cycles of wild-type FUS(LC) or fewer cycles ofmutant
FUS, were poorly soluble in RIPA buffer but fully soluble in 8 M
Figure 4. Recombinant FUS Generates
Liquid Droplet-Like Assemblies, the Revers-
ibility of which Is Reduced by ALS/FTD
Mutants
(A) (Left panel) SHSY5Y cells transiently trans-
fected with YFP-tagged wild-type FUS show static
intranuclear spherical structures. (Top) In the same
cell type, mutant FUS localizes in the cytoplasm as
mobile spherical structures (‘‘droplets’’) that move,
fuse, and disappear (middle and bottom—time
series of two fusion events). (Right panel) Cooling
of 1–5 mM solutions of either full-length FUS or
FUS(LC) domain, induces spontaneous phase
transition into liquid droplets, which spontane-
ously fuse (*), split over seconds, and redisperse
into solute over 50 min.
(B) Full-length FUS(WT) liquid droplets are more
labile than full-length mutant FUS or FUS(LC)
droplets. Both mutant and wild-type FUS proteins
form multiple bright spherical liquid droplets after
cooling (left column). FUS(WT) droplets almost
completely disperse by 50 min at 23C (right
column). FUS proteins containing ALS/FTD mu-
tants formed more stable droplets, many of which
were still visible at 50 min at 23C. The residual
mutant assemblies had darkly refractile proper-
ties, angular edges, and/or spiculated appear-
ances. We interpret these structures to represent
further phase transitions to gel-like or solid as-
semblies. Spiculated assemblies were especially
prevalent with the FUS(LC) constructs, where
virtually all of the residual FUS(LC) material had
this appearance (# in the graph).
Error bars are SEM.urea—again like pathological FUS deposits in human and
C. elegans tissues (Figure 5C, top panel). Furthermore, negative
stain electron microscopic (EM) analysis of recombinant irre-
versible FUS(LC) assemblies revealed a loose meshwork of fi-
brils, the diameter of which (14.00 ± 1.0 nm, n = 20 fibrils) was
indistinguishable from that of fibrils from brain tissue of a human
with a FUS-P525Lmutation (14.4 ± 3.4 nm, n = 56 fibrils, p =N.S.,
Figure 5C, bottom panel) (Uchikado et al., 2006). The EM struc-
ture for reversible FUS assemblies could not be assessed
because their lifetimes in the reversible state (minutes) is shorter
than the time required to fix and prepare them for EM analysis.
Nevertheless, these observations suggest that the recombinantNeuron 88, 678–690, NFUS assembliesmodeled here accurately
reflect those occurring in vivo in human
tissue.
Single Particle and GFP Tracking
Gel Measurements
To further investigate the biophysics of
these phase transitions, we used single
particle tracking methods (Crocker and
Grier, 1996; Rees et al., 2013) to mea-
sure changes in the apparent viscosity
between liquid/liquid droplet, reversible,
and irreversible gel-like FUS states.Briefly, 20-nm radius fluorescent beads were dispersed within
a 15-ml volume of FUS solution, which was then cycled through
different phases. The Brownian movement of the beads was
then used to infer apparent viscosities of the FUS assemblies
in each phase. Wild-type FUS(LC) assemblies in liquid state
prior to, and immediately after a single round of assembly, dis-
played very low dynamic viscosity that is typical of a liquid (Fig-
ure 5D, left bars: 0.4 ± 0.03 Pa s). When wild-type FUS(LC)
formed a reversible gel, there was a modest increase in viscos-
ity (Figure 5D, middle bars: 3.8 ± 0.4 kPa s), which is similar to
the viscosity reported for P-granules (1.0 Pa s)(Brangwynne
et al., 2009). In contrast, mutant FUS(LC) assemblies behavedovember 18, 2015 ª2015 The Authors 683
Figure 5. Recombinant FUS Generates Gel-
Like Assemblies, the Reversibility of which
Is Reduced by ALS/FTD Mutants
(A) Purified recombinant FUS(LC) forms clear so-
lution at 23C (Top left panel) but forms reversible
gel-like structures at 4C (Top center panel). Re-
warming to 23C reverts FUS(LC) to a liquid state
(top left panel). Repeated cycling of wild-type
FUS(LC) eventually results in the formation of
irreversible gels (top right panel).
(B) 4 to 5 assembly/disassembly cycles can be
achieved by wild-type FUS(LC) (black bar) and by
FUS(LC) containing benign polymorphic variants
(P21H and N63S, white bars). ALS/FTD mutations
(gray bars) dramatically reduce the number of
cycles to%1 before irreversibility (**p < 0.01).
(C) Top panel: Coomassie gel (left) and western
blot (right) of RIPA- and 8 M urea solubilisation of
FUS(LC) reveal that liquid state FUS(LC) is fully
soluble in RIPA buffer. Irreversible FUS(LC) is
partly soluble in RIPA, but fully soluble in 8 M urea.
Bottom panel: Transmission electron microscopy
of human FUS inclusions ([Ci]–[Civ]) and irrevers-
ible recombinant protein gels ([Cv]–[Cviii]). Both
are composed of loose networks of14 nm fibrils.
Scale bars are 500 nm ([Cv] and [Cvi]) and 100 nm
([Cvii] and [Cviii]).
(D) Analysis of liquid, reversible gel, and irrevers-
ible gel using fluorescent particle tracking revealed
that liquid (left cluster) and reversible gels (black
bars, middle cluster) have viscosities similar to
those of P-granules. Mutant reversible gels (gray
bars, middle cluster) were more viscous than wild-
type reversible gels. Irreversible gels, regardless of
whether made from wild-type or ALS/FTD mutant
FUS exhibit very high viscosities. N.S., not signif-
icant; **p < 0.01.
Error bars are SEM.very differently. In initial liquid state, mutant FUS(LC) had very
low dynamic viscosity similar to that of wild-type FUS(LC)
((FUS(LC)(S96del) = 0.04 ± 0.02 Pa s; FUS(LC)(G156E) =
0.013 ± 0.002 Pa s; p = N.S.) (Figure 5D, left bars). However,
mutant FUS(LC) that had been assembled once, but was still
reversible, displayed a much greater viscosity compared to
that of once-gelled wild-type FUS(LC) (FUS(LC)(S96del) =
12 ± 6 kPa s; FUS(LC)(G156E) = 10 ± 1.7 kPa s; p = 0.001)
(Figure 5D, middle bars). Even more dramatically, irreversible
assemblies, regardless of whether generated using wild-
type or mutant FUS(LC), had extremely high viscosities
(FUS(LC)(WT) = 15 ± 3 kPa s; FUS(LC)(S96del) = 12 ± 8 kPa
s; FUS(LC)(G156E) = 17 ± 2 kPa s, p = N.S.) (Figure 5D, right
bars). The very high viscosity values for irreversible FUS as-
semblies are fully consistent with the electron microscopic684 Neuron 88, 678–690, November 18, 2015 ª2015 The Authorsstructure of these assemblies as loose
meshworks of intertwined fibrils that
fulfil the IUPAC definition of a hydrogel
(Figure 5C). These results support
the hypothesis that FUS assemblies
can phase-transition between (i) soluble
monomeric/liquid droplet like states, (ii)reversible hydrogel-like states, and (iii) irreversible, fibrillar hy-
drogel-like states.
Mutant FUS Assemblies Trap Other RNA Binding
Proteins
We reasoned that condensation of mutant FUS into higher-order
assemblies might alter binding and release of RNP granule
cargo. To test this idea, we mixed mutant or wild-type FUS(LC)
with GFP-tagged SMN (or in separate experiments, with GFP-
STAU-1). The mixtures were cooled to induce phase transition
and assembly, and buffer was layered on top. The diffusion of
SMN (or STAU-1) into the overlying buffer layer was then
measured by fluorescence. Very little SMN or STAU-1 was de-
tected in the buffer above any of the gelled assemblies (black
bars labeled G-gel in Figure 6A.), regardless of whether the
Figure 6. Mutant FUS Forms Poorly Revers-
ible Gels, which Fail to Release Cargo such
as SMN and STAU-1
(A) When recombinant GFP-tagged SMN (or
STAU-1) protein is mixed with FUS(LC) protein and
gel assembly is induced by cooling, little SMN (or
STAU-1) is released into the buffer (as measured
by fluorescence) regardless of whether the FUS
gel is derived from wild-type or ALS/FTD mutant
FUS(LC) (black bars). When the gel is reversed by
warming to 23C (white bars), significant SMN (or
STAU-1) protein is released into the buffer from
FUS(WT) hydrogels. Very little SMN (or STAU-1) is
released by the irreversible ALS/FTD mutant
FUS(LC) gels (gray bars;**p < 0.001).
(B) Fluorescent molecule tracking in liquid,
reversible gel, and irreversible gel assemblies re-
veals that in liquid state, SMN and STAU-1 diffuse
rapidly at 1–4 mm/s in both mutant and wild-type
samples (left two columns). On formation of a gel
(center two columns), movement of SMN and
STAU-1 is constrained (<1 mm2/s). On rewarming,
reversible FUS(WT) gels disassemble and release
SMN and STAU-1. The irreversible mutant gels
continue to constrain movement of SMN and
STAU-1. Image stacks are captured at 29 Hz; pixel
width corresponds to 160 nm on the specimen.
Representative areas are boxed and visualized in a
1.3 mm2 plot, color coded to the diffusion coeffi-
cient fitted to each track.
Error bars are SEM.gels were composed of mutant or wild-type FUS(LC). However,
SMN and STAU-1 were rapidly released into the buffer following
melting of reversible gels compose of wild-type FUS(LC) or
non-pathogenic FUS(LC) variants (P21H or N63S) (white bars
labeled L-liquid in Figure 6A). However, gels composed of either
of the pathogenic mutants (S96del or G156E) failed to revert to
liquid states and, as a result, retained SMN and STAU-1 (gray
bars labeled G’, Figure 6A). These experiments reveal that
cargo proteins can be retained by pathological irreversible FUS
assemblies.
To provide further support for the notion that irreversible FUS
assembliesmight trap cargo RNPs, we used single-molecule im-
aging to track movement of individual GFP-tagged SMN and
GFP-tagged STAU-1 molecules within mutant and wild-type
FUS assemblies. Both SMN and STAU-1 moved freely in
never-gelled liquid preparations of wild-type and mutant FUS
(diffusion coefficients: 1–3 mm2/s; Figure 6B, left two columns).Neuron 88, 678–690, NFollowing phase transition and assembly,
the diffusion coefficients of both SMN
and STAU-1 decreased substantially in
reversible assemblies of both wild-type
and mutant FUS(LC) (<<1 mm2/s) (Fig-
ure 6B, center two columns). Fast diffu-
sion of SMN and STAU-1 returned when
the reversible FUS(WT) assembly was
melted at 23C (Figure 6B, top right, col-
umns). In contrast, despite re-warming,
irreversible FUS assemblies comprisedof either twice-cycled mutant FUS or multiply cycled wild-type
FUS, continued to significantly constrain movement of SMN
and STAU-1 (Figure 6B, bottom right columns).
Mutant FUS Reduce New Protein Synthesis in Neuronal
Axons and Termini
Taken together, our experiments demonstrate that mutant FUS
has an increased propensity to form irreversible assemblies
that could disrupt the function of FUS-containing RNP granules
in several, non-mutually exclusive ways. For instance, irrevers-
ible RNP granules containingmutant FUS could disturb the intra-
cellular transport of those RNP granules (Alami et al., 2014; Liu-
Yesucevitz et al., 2014). Alternatively, mutant FUS assemblies
could trap and titrate out key factors. In the nucleus, this could
affect transcription and splicing. In the cytoplasm, and particu-
larly in specific subcellular niches such as dendrites and axon
terminals, the trapping could impair local RNA metabolism andovember 18, 2015 ª2015 The Authors 685
Figure 7. Mutant FUS and FUS(LC) Domain, but Not Full-Length
Wild-Type FUS, Cause Reduced New Protein Synthesis When Ex-
pressed in Cultured Neurons
(A) New protein synthesis was detected by puromycylation in axon terminals of
cultured Xenopus retinal ganglion neurons (left panel: phase contrast; right
panel: anti-puromycin fluorescent images) expressing equivalent quantities of
full-length FUS(WT) or various mutant and truncated human FUS proteins.
Scale bar, 10 mm.
(B) Under basal conditions, de novo protein synthesis is equivalent in non-in-
jected neurons, and in neurons expressing FUS(WT). However, de novo protein
synthesis was significantly reduced in neurons expressing ALS/FTD mutants
including: FUS(R522G), FUS(R524S), FUS501, FUS(R495X), and in gelling-
prone FUS(LC)(WT), FUS(LC)(S96del), FUS(LC)(G156E), FUS(LC)(P21H), and
FUS(LC)(N63S). In good agreement with the in vivo studies in C. elegans, heat
shock causes significant reduction of new protein synthesis in neurons ex-
pressing mutant FUS, but minimal impact on non-transfected and FUS(WT)
expressing neurons (right panel). N.S., not significant; *p < 0.05, **p < 0.01, and
***p < 0.001.
Error bars are SEM.translation, thereby converting irreversible FUS RNP granules
into local translation repressors. This possibility is distinctly likely
because both TIA-1 and mutant FUS are present in stress gran-
ules, which act as translational repressors (Anderson and Keder-
sha, 2002; Bosco et al., 2010; Decker and Parker, 2012).
To assess the latter hypothesis, we investigated de novo pro-
tein synthesis in axon terminals of primary Xenopus retinal neuron
cultures expressing equivalent quantities of human full-length686 Neuron 88, 678–690, November 18, 2015 ª2015 The AuthorsFUS(WT), full-length mutant FUS, wild-type FUS(LC), pathogenic
mutant FUS(LC), or non-pathogenic FUS(LC) variants (Fig-
ure S15). Newly synthesized proteins were detected by pulse
labeling with puromycin. The released truncated puromyciny-
lated proteins were imaged and quantified by immunofluores-
cence using an anti-puromycin antibody (Lin et al., 2009; Schmidt
et al., 2009; tom Dieck et al., 2015) (Figure 7A). Under basal
conditions, new protein synthesis was significantly reduced
in axons expressing full-length FUS(R522G) (0.86 ± 0.02),
FUS(R524S) (0.72 ± 0.02), FUS501 (0.85 ± 0.03), and FUS(R495X)
(0.82 ± 0.02) (Figure 7B, left panel, p < 0.001). Following heat
shock using the identical paradigm employed in C. elegans,
new protein synthesis was further reduced in all neurons express-
ing mutant FUS, but not in non-injected neurons or neurons ex-
pressing FUS(WT) (Figure 7B, center panel, p < 0.01). This result
precisely mirrors the effect of the same heat shock paradigm on
in vivo toxicity of mutant FUS in C. elegans. Additionally, and
again in good agreement with the in vivo neurotoxicity studies
in C. elegans, new protein synthesis was significantly decreased
in neurons expressing FUS(LC), and this was further worsened
by the S96del or G156E ALS/FTD mutants (FUS(LC)(WT)
(0.72 ± 0.02), FUS(LC)(S96del) (0.68 ± 0.02), and FUS(LC)(G165E)
(0.52 ± 0.02), FUS(LC)(P21H) (0.89 ± 0.03), FUS(LC)(N63S)
(0.86 ± 0.03), Figure 7B, left panel, p < 0.001). Treatment of neu-
rons expressing wild-type or mutant FUS with cyclohexamide
was used as a positive control (Figure 7B, right panel).
Our interpretation of these results is that mutant FUS assem-
blies perturb RNP granule function by trapping key components
of the RNA metabolism and translation machinery. However, an
alternate possibility is that the inhibition of new protein synthesis
arises from cellular stress due to accumulation of misfolded FUS
proteins.While there are several non-specific forms of stress that
might differentially occur in animals and cells expressing mutant
FUS, the type of stressmost clearly associatedwith the accumu-
lation of misfolded proteins and with inhibition of new protein
synthesis is the unfolded protein response (UPR), also known
as the endoplasmic reticulum (ER) stress response. Traditionally,
the UPR has only been associated with accumulation of mis-
folded proteins in the ER. However, in some models of neurode-
generative diseases, intracellular misfolded non-ER resident
proteins have also been noted to activate the UPR and attenuate
protein synthesis (Moreno et al., 2013; Nishitoh et al., 2002).
To address this possibility, we undertook three experiments:
the first two, in vivo in our C. elegansmodel; the third, in cultured
Xenopus neurons.
We have previously noted that C. elegans expressing either
full-length wild-type FUS or full-length mutant FUS had very
few intra-cytoplasmic stress granules (zero to two per neuron;
p = N.S.) (Murakami et al., 2012). However, animals expressing
FUS (WT) and animals expressing mutant FUS are all clearly
capable of mounting a vigorous stress response after heat
shock, displaying abundant stress granules (five to six gran-
ules/cell) (Figure 8, left panel; p = N.S.). These in vivo observa-
tions suggest that (1) animals expressing mutant or wild-type
FUS are capable of mounting a stress response and (2)
mutant-expressing animals are not more stressed by accumula-
tion of misfolded mutant FUS than are animals expressing wild-
type FUS.
Figure 8. Neurotoxicity of Mutant FUS in
C. elegans and Reduced New Protein Syn-
thesis in Xenopus Neurons Are Unlikely to
beDue toActivation of theUPRdue to Accu-
mulation of Misfolded FUS
(A) In vivo stress granule density measured by
counting pab-l-positive granules in C. elegans
under basal conditions and after heat shock were
not different between control (empty vector);
FUS(WT) and mutant FUS animals, indicating that
mutant FUS animals were not under greater
unfolded protein stress.
(B) Thapsigargin treatment induced UPR and
reduced new protein synthesis in Xenopus neurons
expressing FUS(WT). PERK1 inhibitors rescued
reduced protein synthesis in thapsigargin-treated
neurons expressing FUS(WT), but not mutant FUS-
expressing neurons.
Error bars are SEM.Second, we examined the activity of the UPR in our C ele-
gans model. Translation repression in the UPR is mediated by
the eIF2a kinase PERK, and it can be substantially reversed
by PERK kinase inhibitors or by PERK deletion. We used
RNAi to completely ablate detectable mRNA expression for
the endogenous C. elegans PERK homolog (pek-1) and the
other eIF2a kinase of worms (gcn-2) (Mao and Crowder,
2010; Scheuner et al., 2001). Despite the complete loss of
pek-1 and gcn-2, there were no changes in the motor function
and lifespan in pek-1 or gcn-2 RNAi-treated mutant FUS-ex-
pressing animals (Figures 2A and 2B). These results confirm
that neurotoxicity induced by mutant FUS is not directly attrib-
utable to activation of PERK (or of eIF2a phosphorylation by
other means), and hence, neurotoxicity is unlikely to reflect
activation of the UPR.
Third, we undertook PERK inhibitor studies in the Xenopus
neuron culture model. We compared the effect of the PERK ki-
nase inhibitor GSK2606414 (Axten et al., 2012) on new protein
synthesis in neurons expressing (i) wild-type FUS, (ii) wild-
type FUS plus thapsigargin (a well-established activator of the
UPR), and (iii) ALS/FTD mutant FUS: FUS(R522G), FUS(R524S),
FUS501, or FUS(R495X). The UPRwas induced, and new protein
synthesis was stalled by thapsigargin treatment in neurons ex-
pressing full-length FUS(WT) (Figure 8, right panel, lane 3). The
UPR was blocked, and new protein synthesis was restored in
FUS(WT) neurons treated with GSK2606414 (Figure 8, right
panel, lane 4). However, equivalent doses of the inhibitor failed
to reverse the impaired new protein synthesis in neurons ex-
pressingmutant FUS (Figure 8, right panel, lanes 6, 8, 10, and12).
DISCUSSION
A detailed explanation of how ALS/FTD-associated mutations in
RBPs might impact neuron biology would increase our under-
standing both of the molecular origins of these neurodegenera-
tive disorders and of the biology of nuclear and cytoplasmic
RNP granules. Our work provides several important insights
into these issues.
First, the biochemical and biophysical experiments reported
here support a physiological model in which reversible phasetransition of LC-containing proteins such as FUS can be used
to control the assembly and the function of membrane-free struc-
tures such as nuclear and cytoplasmic RNPgranules. Thus, aswe
have shown, various cargo elements such as other RNP proteins
can be concentrated into a dimensionally constrained space dur-
ing liquid droplet and reversible hydrogel formation and then
released upon their dissolution. The biophysics of conversion
from liquid droplet to reversible hydrogel is not yet clear, but
they differ only slightly in viscosity, and reversible hydrogelsmight
reflect the partial polymerization into a loose but reversible fibrous
network that provides more stability for longer-lived granules.
However, the biophysical propensity of LC-containing pro-
teins to undergo phase transitions to liquid droplets and hydro-
gels also renders them vulnerable to further condensation into
hyper-stable structures. Thus, we have shown that ALS/FTDmu-
tations in FUS dramatically increase the propensity to undergo
phase transition into stable ‘‘irreversible’’ fibrillar hydrogel-like
states. Indeed, even wild-type FUS can eventually be induced
to phase shift into fibrillar hydrogel form—an observation that
provides a mechanism for the occurrence of irreversible FUS as-
semblies in cases of sporadic ALS/FTD with FUS pathology, but
without mutations in FUS.
We show that FUSassembly is largely driven by the LCdomain.
However, our biophysical modeling suggests that other parts of
the protein (especially the C terminus) likely buffer this tendency
and render the overall protein less prone to form higher order as-
semblies (Figures S1–S4). Our biophysical modeling also sug-
gests that mutations in the LC domain might directly increase
the propensity of the LC domain to form irreversible gels, while
mutations in the C terminus are likely to indirectly increase the
risk of phase transition by reducing the anti-assembly property
of the C terminus (Figures S1–S4). Still other mutationsmay affect
this process by altering binding of RNA or other proteins, which
are known to nucleate FUS assembly (Schwartz et al., 2013).
Our work suggests that stable fibrillar hydrogels induce
toxicity by mechanisms different from conventional amyloids,
namely by disrupting RNP granule function. This conclusion is
supported by the fact that downregulating the expression of
other RNP granule components destabilizes the pathological
RNP granules and rescues toxicity.Neuron 88, 678–690, November 18, 2015 ª2015 The Authors 687
Perturbation of RNP granule function could induce neurotox-
icity through several mechanisms. Our results strongly suggest
that one, but not necessarily the only, neurotoxic effect of phase
transition into irreversible higher order assemblies is to disrupt
the function of cytoplasmic RNP granules, thereby reducing
new protein synthesis in intracellular compartments, such as
axon terminals, that are heavily dependent on local translation
control by RNP granules (Akbalik and Schuman, 2014; Holt
and Schuman, 2013; Jung et al., 2014). This effect would be pre-
dicted to be most severe in dendrites and axon terminals of long
projection neurons (e.g., motor neurons affected in ALS). The
reduction in local new protein synthesis could arise through
several molecular mechanisms that are not mutually exclusive,
including: altering intracellular transport of FUS granules (Alami
et al., 2014; Liu-Yesucevitz et al., 2014), and, as we have shown
here, trapping cargo proteins (e.g., TIAR-1) involved in regulating
local RNA metabolism and translation.
It is quite probable that similar phase transitions in nuclear
FUS might also induce changes in RNA transcription and
splicing, which could contribute to toxicity.
Looking forward, it will be important to catalog the differen-
tial RNA and protein components of normal and pathological
FUS assemblies in ALS and in FTD and to discover the
signaling events that govern their assembly and disassembly.
Understanding the basis for these processes may provide an
explanation for the different clinical phenotypes induced by
FUS assemblies. More importantly, as we have shown, manip-
ulation of molecular components of pathological RNP granules
(like STAU-1 and SMN) to destabilize pathological assemblies
and manipulation of the signaling pathways that govern as-
sembly and disassembly of physiological and pathological
RNP granules might be tractable therapeutic targets for these
diseases.
The observations reported here are likely to pertain to neu-
rodegenerative diseases associated with TDP-43, TAF15, EWS,
hnRNPA1, and B2. Impaired degradation and removal of these
assembly-prone proteins could also explain the occurrence of
pathological assemblies of these proteins (particularly TDP-43)
in ALS/FTD caused by mutations in autophagy pathway genes
such as p62, optineurin, TBK-1, and valosin-containing protein-1.
EXPERIMENTAL PROCEDURES
Transgenic FUS animals
C. elegans stably expressing FUS(WT), FUS(R522G), FUS(R524S), FUS(P525L),
FUS(R495X), andFUS501were generated as described (Murakami et al., 2012).
FUS501 mimics human pathogenic truncation mutants such as FUS
G497AfsX527(Yan et al., 2010), K510WfsX517X (Yan et al., 2010), G472X
(Hara et al., 2012), G466VfsX15 (DeJesus-Hernandez et al., 2010), and
R495X(Bosco et al., 2010; Yan et al., 2010) G504Wfs (Kent et al., 2014). Strains
lacking the LC motif or expressing LC motif alone (wild-type, S96del and
G156E) were made similarly. Strains had similar levels of transgene expression.
C. elegans hsp-70, pab-1, stau-1, smn-1, tiar-1 and hrp-1 cDNAs were in-
jected into lin-15 animals together with FUS constructs to generate double
transgenics.
Animals and Human Tissues
Experiments onC. elegans and Xenopuswere conducted using approved pro-
tocols at the University of Toronto and University of Cambridge. Post-mortem
human brain and spinal cord tissues were obtained from four unrelated sub-688 Neuron 88, 678–690, November 18, 2015 ª2015 The Authorsjects with FUS(P525L) using institutionally approved protocols at Mayo Clinic
(D. Dickson) and Columbia University (N. Shneider).
Thrashing Assay, Heat Shock Treatment, and Small Molecule
Compound Treatment
Motor activity was assessed by counting body bending for 1 min in 4-day-old
adultC. elegans (Gao and Zhen, 2011). Heat shock involved incubation at 30C
for 6 hr, and then at 22C, repeated daily for 3 days (Murakami et al., 2012).
Scyllo-inositol (100 mM, IO631, TCI America) was added to the media.
Electron Microscopy
Anterior horns of formalin-fixed spinal cord were removed, infiltrated, and
embedded in LR White resin (Polysciences). Sections were stained with 2%
uranyl acetate and lead citrate and examined with a Philips 208S electron mi-
croscope. Recombinant FUS(LC) was diluted to 0.2 mM, blotted onto Formvar
grids, stained with 1%phosphotungstic acid (PTA, pH 7.0), and examinedwith
a Hitachi 7000 electron microscope at 75 kV (Morita et al., 2009).
Live Cell Imaging
Human Neuroblastoma cell line, SH-SY5Y, was transfected using Neon Trans-
fection System (Life Technologies). After 12 hr incubation, cells were stained
and visualized with 710 Zeiss confocal microscope.
RNAi Assay of C. elegans Strains
RNAi was performed as previously (Dixon et al., 2006; Kamath et al., 2003).
Sequential Fractionation and Western Blot Analysis
Animals were lysed in ten volumes (v/w) of 50 mM Tris-HCl, 750 mM NaCl,
10 mM NaF, and 5 mM EDTA (pH 7.4) with sonication. The lysate was centri-
fuged and supernatant was collected (high-salt-soluble fraction). The proce-
dure was repeated sequentially in RIPA buffer, 2% SDS buffer, and 8 M urea
buffer as described (Murakami et al., 2012).
RNA Granule Colocalization and GFP Intensity Measurement
Cytoplasmic RFP-positive, GFP-positive, and double-positive granules were
counted in tail neurons of double transgenic animals co-expressing GFP-
tagged-FUS and RFP-tagged stau-1, smn-1, tiar-1, or hrp-1.
Single Particle Tracking Analysis in FUS Droplets and Gels
Samples were imaged on a Nikon TE-300 inverted wide-field fluorescence mi-
croscope and laser illumination (Cobalt, 488 nm wavelength laser attenuated
to 2 mW/cm2 intensity on the specimen for imaging GFP, and Toptica iBeam
smart 640 nm laser at 20 mW/cm2 for imaging fluorescent spheres). Images
were captured from a focal plane 15 mm above the coverslip to ensure the ob-
servations measured the particles in the bulk specimen and not any adhering
to the coverslip. Particle track analysis was performed as described (Crocker
and Grier, 1996; Rees et al., 2013). Each repeat measurement of viscosity was
obtained from a separate specimen, and at least four image stacks were
measured for each.
Expression, Purification, and Gelling of Recombinant FUS LC
Domain Constructs
cDNAs for FUS LC residues 2–214 and its variants were cloned (pOPINS vec-
tor) and expressed in E. coli BL21(DE3), purified on Ni-NTA resin, buffer
exchanged into either droplet buffer (50 mM Tris and 150 mM NaCl [pH 7.5])
or gelation buffer (50 mM Tris and 500 mM NaCl [pH 7.5]). For gelling experi-
ments, FUS samples were concentrated to 1 mM, transferred to thin-walled
PCR tubes and incubated at 4C, and transferred to 23C to induce melting.
For liquid droplet assays, samples were adjusted to 1–5 mM FUS, and 20 ml al-
iquots were spotted onto siliconised coverslips, cooled to 4C, and imaged at
403 on an EVOS FL microscope.
GFP-SMN/STAU-1 Release Fluorescence Assay
Human SMN or STAU-1 with N-terminal His8-GFP tagwere expressed and pu-
rified as for FUS constructs, including a gel filtration step. 5 ml of 10 mM GFP-
SMN or GFP-Stau1 protein wasmixed with 100 ml of 1 mMwild-type or mutant
FUS LC and then incubated at 4C until gelling occurred. Gels were overlaid
with 100 ml of 50 mM Tris with 500 mM NaCl (pH 7.5) buffer; transferred to
23C to melt; and monitored by fluorescence for release of GFP-SMN or
GFP-Stau1.
Retinal Cultures and Puromycin Labeling
Xenopus laevis embryos were fertilized in vitro and raised in 0.13 Modified
Barth’s Saline at 14C–18C. Capped mRNAs of wild-type or mutant FUS
were made (SP6 kit (Ambion)), polyadenylated using Poly(A)-tailing kit, and in-
jected into the two dorsal blastomeres at four-cell stage. Eye primodia from
stage 24–26 embryos were dissected and cultured in 60% L-15 on laminin-
coated coverslips at 20C for 48 hr (basal condition), or at 20C for 42 hr
followed by 6 hr at 30C (heat shock treatment). For puromycin labeling, cul-
tures were treated with 1.8 mM puromycin for 15 min, labeled with Alexa Fluor
488 conjugated anti-puromycin antibody (1:250, Millipore), and imaged as
described (Lin et al., 2009; Schmidt et al., 2009; tom Dieck et al., 2015). The
fluorescent intensities of 80–250 growth cones per sample were collected. Ex-
periments were performed in three to four replicates.
Statistical Analysis
Unpaired Student’s t tests, Fisher’s exact test, and ANOVA were performed
with SigmaPlot version 11.0.
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